PhamarEngine, Inc.
- Began operation in February 2003
- # of Employees: 33 (2024 Annual Report)
- Product: ONIVYDE®
- R&D Focus: Oncology
- Chairperson: Jan-Yau Hsu
- President & CEO: Hong-Ren Wang, Ph.D.
- Spokesperson: ChiHsin Chang
- HQ: Taipei, Taiwan
- Investor Contact: info@pharmaengine.com
Latest News
-
2025-08-20
PharmaEngine announces TFDA approval of PEP08 Phase 1 clinical trial for solid tumor cancers
-
2025-07-22
PharmaEngine announces Phase I clinical study of PEP08 has been approved by Australia HREC and acknowledged by Australia TGA
-
2025-04-28
PharmaEngine to present three posters in AACR 2025